Clinical Trial Update: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial of bococizumab in adults with hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events has completed, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Dyslipidemia
• Hyperlipidemia

Drugs mentioned

• Bococizumab (bococizumab)

Snippet

Sponsor: Pfizer | Conditions: Hyperlipidemia | Phase 3 | Status: COMPLETED | Results posted: 2017-07-24